Faropenem 300 mg Twice Daily Dosing
Yes, faropenem 300 mg twice daily (BID) can be given and is the established dosing regimen for this oral carbapenem antibiotic in adults.
Evidence-Based Dosing
The 300 mg BID dosing of faropenem has been validated through multiple high-quality clinical trials:
For acute bacterial sinusitis: Both 7-day and 10-day courses of faropenem 300 mg BID demonstrated clinical cure rates of 80.3% and 81.8% respectively, which were non-inferior to cefuroxime axetil 1
For maxillary sinusitis: The same 300 mg BID regimen for 7 days showed statistical equivalence to cefuroxime axetil (89.0% vs 88.4% clinical cure rates) with excellent bacteriological success rates of 91.5% 2
Spectrum and Clinical Applications
Faropenem at this dosing demonstrates robust activity against common respiratory pathogens:
- S. pneumoniae: 97.3% eradication rate
- H. influenzae: 85.0% eradication rate
- S. aureus: 88.9% eradication rate
- M. catarrhalis: 100% eradication rate 2
The drug is approved for treating upper respiratory tract infections, urinary tract infections, dermatological infections, and periodontal infections 3.
Safety Profile
The 300 mg BID regimen is well-tolerated with drug-related adverse events occurring in only 9.5% of patients, comparable to comparator antibiotics. The most common side effects include:
- Diarrhea (2.2%)
- Nausea/vomiting (1.5%)
- Skin reactions (1.5%)
- Abdominal pain (0.7%) 2
Key Advantages
Faropenem offers distinct benefits as an oral carbapenem:
- Broad-spectrum β-lactamase stability 3
- Low propensity for bacterial resistance 3
- Convenient oral administration versus parenteral carbapenems like meropenem or ertapenem
- Shorter treatment courses (7 days) are as effective as 10-day regimens 1
Important Caveat
Note: The FDA drug label evidence provided 4 actually describes furosemide (a diuretic), not faropenem—this appears to be a data error and should be disregarded for this antibiotic question.